Mirum Pharmaceuticals, Inc.
MIRM
$44.39
-$0.88-1.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 111.59M | 99.41M | 90.38M | 77.88M | 69.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 111.59M | 99.41M | 90.38M | 77.88M | 69.22M |
| Cost of Revenue | 23.02M | 22.78M | 20.81M | 20.23M | 17.83M |
| Gross Profit | 88.57M | 76.63M | 69.57M | 57.65M | 51.39M |
| SG&A Expenses | 57.71M | 56.83M | 50.55M | 49.21M | 45.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 126.77M | 123.64M | 103.06M | 102.11M | 95.69M |
| Operating Income | -15.18M | -24.22M | -12.68M | -24.23M | -26.47M |
| Income Before Tax | -13.65M | -24.37M | -13.89M | -24.00M | -24.66M |
| Income Tax Expenses | 1.03M | -576.00K | 347.00K | 635.00K | 624.00K |
| Earnings from Continuing Operations | -14.68M | -23.79M | -14.24M | -24.64M | -25.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.68M | -23.79M | -14.24M | -24.64M | -25.28M |
| EBIT | -15.18M | -24.22M | -12.68M | -24.23M | -26.47M |
| EBITDA | -9.13M | -18.17M | -6.63M | -18.38M | -20.80M |
| EPS Basic | -0.30 | -0.50 | -0.30 | -0.52 | -0.54 |
| Normalized Basic EPS | -0.17 | -0.32 | -0.18 | -0.32 | -0.33 |
| EPS Diluted | -0.30 | -0.50 | -0.30 | -0.52 | -0.54 |
| Normalized Diluted EPS | -0.17 | -0.32 | -0.18 | -0.32 | -0.33 |
| Average Basic Shares Outstanding | 48.89M | 47.52M | 47.78M | 47.24M | 46.93M |
| Average Diluted Shares Outstanding | 48.89M | 47.52M | 47.78M | 47.24M | 46.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |